PatentAug 12, 2026, 07:06 AM
Alterity Therapeutics Secures Patent for ATH434 Until 2045
AI Summary
Alterity Therapeutics announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for ATH434, its lead clinical asset. This patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential. The new patent strengthens ATH434’s intellectual property as it advances toward Phase 3 development in Multiple System Atrophy (MSA) and enables future development for Parkinson’s disease and other neurodegenerative disorders.
Key Highlights
- USPTO granted a new composition of matter patent for ATH434.
- Patent extends protection for ATH434 to at least 2045.
- Strengthens ATH434's intellectual property portfolio.
- Enables future development of ATH434 for Parkinson's disease.
- ATH434 is advancing toward Phase 3 development in MSA by year-end 2026.
- The patent covers a crystalline structure of ATH434 mesylate.
- Expected to be listed in the FDA's Orange Book upon approval.
Price Impact
More from ATHE